Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
CORIA is an observational cohort study of immunosuppressed populations who test positive for
 COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated
 with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid
 organ transplant. Participants will have routine clinical data collected with optional
 baseline collection and storage of a blood sample for storage . The study will be conducted
 in up to 30 sites within Australia.
Inclusion Criteria:

 1. Presenting (in person or via telemedicine) for evaluation because they:

 -  Have clinical symptoms consistent with for COVID-19:

 -  Fever (≥ 37.8 °C) on examination OR patient reported fever (≥ 37.8 °C) or
 feverishness (felt febrile but did not take temperature) OR any of, cough, sore
 throat, shortness of breath, rhinorrhoea, headache, chills, generalise myalgia,
 malaise, fatigue, confusion, diarrhea, nausea or vomiting

 -  Have been contacted because they have been identified as a contact to a confirmed
 case

 -  Have been contacted and told they tested positive for COVID-19

 2. Have one of the following conditions affecting immune function:

 -  Known or suspected primary immunodeficiency, defined as a predisposition to
 infection associated with an apparent or presumed deficit of immune function

 -  On immunosuppressive therapy

 -  Treatment with immune checkpoint inhibitors within 36 months of enrolment date

 -  HIV infection

 -  Diagnosis of cancer within 36 months of enrolment date, excluding superficial
 basal cell and squamous cell carcinomas

 -  Solid organ transplantation

 3. For optional biobanking only, ability to provide informed consent

 Exclusion Criteria:

 -  Nil